RBT Expands into Cancer Immunotherapy with Innovative CIK Cell Treatments

Vilnius, Lithuania – October 2024 – In a ground-breaking development, RBT Global has introduced Cytokine-Induced Killer (CIK) cell therapy as part of its advanced cancer treatment portfolio. This novel approach harnesses the patient’s own immune cells, reprogramming them to seek out and destroy cancerous cells.

The therapy, already in clinical trials in several European countries, has shown promising results in enhancing immune response and targeting tumours with high precision. “CIK therapy is a major breakthrough in our fight against cancer,” commented

Dr. Darinskas. “We believe this personalised immunotherapy can transform outcomes for patients with aggressive malignancies.”

RBT Global’s focus on developing cutting-edge treatments underscores its commitment to pushing the boundaries of traditional medicine and offering hope to patients worldwide​​​.